Merck Canada and MaRS Team Up to Launch Lung Cancer Innovation Challenge Challenge aimed at improving patient outcomes by identifying solutions to reduce time between diagnosis and treatment for lung cancer patients Merck Canada and MaRS Discovery District are proud to launch the Lung Cancer Innovation Challenge . The competition challenges Ontario -based innovators to identify, implement and scale solutions that can enhance an Ontario lung cancer patient’s journey by seeking to reduce … Challenge aimed at improving patient outcomes by identifying solutions to reduce time between diagnosis and treatment for lung cancer patients Merck Canada and MaRS Discovery District (MaRS) are proud to launch the Lung Cancer Innovation Challenge . The competition challenges Ontario -based innovators to identify, implement and scale solutions that can enhance an Ontario lung cancer patient’s journey by seeking to reduce the length of time between diagnosis and treatment for lung cancer patients, and enable improved treatment outcomes, especially for priority patient groups such as rural and lower socioeconomic populations in Ontario . Financial prizes will be awarded to the winners of the challenge. In addition, the winners may have the opportunity to collaborate on future projects with Merck Canada. Of the four most common cancers, lung cancer, has the lowest survival rate, regardless of stage at diagnosis. 1 It is estimated that 29,800 new lung cancer cases would be diagnosed in 2020 across Canada with almost 40 per cent of those cases residing in Ontario alone. 2,3 The ability for lung cancer patients to receive initial access to primary care and the proper treatment at the right time is dependent upon a number of different factors that touch on the patient, their circle of care, and the broader health system.